{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T07:20:00Z","timestamp":1794900000242,"version":"4.9.1"},"reference-count":36,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"32","license":[{"start":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T00:00:00Z","timestamp":1754611200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,8,8]]},"abstract":"<jats:p>Papillary thyroid carcinoma (PTC) is the most common type of thyroid cancer. The primary challenge is identifying patient subgroups with PTC and choosing the most effective treatment approach. To explore the differentially expressed proteins (DEPs) between high and low recurrent-risk PTCs, we collected 15 tissues comprising high (n\u2005=\u20057) and low (n\u2005=\u20058) recurrent-risk groups from PTC. The samples were detected by tandem mass tag labeling proteomics. Using The Cancer Genome Atlas data on thyroid cancer, prognosis-related DEPs were identified. Furthermore, an immunohistochemistry stain of 53 cases of PTC tumors was adopted to validate the relation of potential biomarkers with prognosis. We identified 8958 proteins from the 15 samples, with 95 DEPs obtained by comparing high and low recurrent-risk groups, including 38 upregulated and 57 downregulated proteins. Three downregulated proteins (protein S [PROS1], clusterin [CLU], and leucine-rich \u03b1-2-glycoprotein 1 [LRG1]) were found to be significantly associated with poor overall survival in thyroid cancer using differential analysis and Kaplan\u2013Meier survival analysis. Immunohistochemistry results showed low or moderated expressions of PROS1, CLU, and LRG1 were significantly associated with high-risk clinicopathologic characteristics of PTC. PTC patients with higher expression of PROS1, CLU, and LRG1 had better progression-free survival than those with low or moderate expression. Our study identified PROS1, CLU, and LRG1 as novel prognostic biomarkers in PTC.<\/jats:p>","DOI":"10.1097\/md.0000000000043715","type":"journal-article","created":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T19:01:55Z","timestamp":1755198115000},"page":"e43715","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Quantitative proteomics analysis of papillary thyroid carcinoma reveals protein S, clusterin, and leucine-rich \u03b1-2-glycoprotein 1 as potential prognostic protein biomarkers"],"prefix":"10.1097","volume":"104","author":[{"given":"Haili","family":"Sun","sequence":"first","affiliation":[{"name":"Nursing Department, the Affiliated Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, P. R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianbiao","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Head and Neck Surgery, the Affiliated Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, P. R. China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nizhen","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Head and Neck Surgery, the Affiliated Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, P. R. China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9015-8930","authenticated-orcid":false,"given":"Kehao","family":"Le","sequence":"additional","affiliation":[{"name":"Department of Head and Neck Surgery, the Affiliated Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, P. R. China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20261117","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality world-wide for 36 cancers in 185 countries.","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"R2-20261117","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1038\/nrendo.2016.110","article-title":"The changing incidence of thyroid cancer.","volume":"12","author":"Kitahara","year":"2016","journal-title":"Nat Rev Endocrinol"},{"key":"R3-20261117","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ecl.2018.10.002","article-title":"Evolving understanding of the epidemiology of thyroid cancer.","volume":"48","author":"Seib","year":"2019","journal-title":"Endocrinol Metab Clin North Am"},{"key":"R4-20261117","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/nrendo.2011.142","article-title":"Molecular genetics and diagnosis of thyroid cancer.","volume":"7","author":"Nikiforov","year":"2011","journal-title":"Nat Rev Endocrinol"},{"key":"R5-20261117","doi-asserted-by":"crossref","first-page":"215","DOI":"10.3803\/EnM.2019.34.3.215","article-title":"Radioactive iodine-refractory differentiated thyroid cancer and redifferentiation therapy.","volume":"34","author":"Liu","year":"2019","journal-title":"Endocrinol Metab (Seoul)"},{"key":"R6-20261117","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1210\/jc.2005-2838","article-title":"Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy.","volume":"91","author":"Durante","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"R7-20261117","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/thy.2015.0020","article-title":"2015 American Thyroid Association Management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer.","volume":"26","author":"Haugen","year":"2016","journal-title":"Thyroid"},{"key":"R8-20261117","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1038\/nature01512","article-title":"Protein analysis on a proteomic scale.","volume":"422","author":"Phizicky","year":"2003","journal-title":"Nature"},{"key":"R9-20261117","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/s41421-022-00471-6","article-title":"Author correction: Artificial intelligence defines protein-based classification of thyroid nodules.","volume":"8","author":"Sun","year":"2022","journal-title":"Cell Discov"},{"key":"R10-20261117","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1002\/1878-0261.12570","article-title":"High-throughput proteomic analysis of FFPE tissue samples facilitates tumor stratification.","volume":"13","author":"Zhu","year":"2019","journal-title":"Mol Oncol"},{"key":"R11-20261117","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1038\/s41596-022-00727-1","article-title":"High-throughput proteomic sample preparation using pressure cycling technology.","volume":"17","author":"Cai","year":"2022","journal-title":"Nat Protoc"},{"key":"R12-20261117","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.cell.2020.05.032","article-title":"Proteomic and metabolomic characterization of COVID-19 patient sera.","volume":"182","author":"Shen","year":"2020","journal-title":"Cell"},{"key":"R13-20261117","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.cell.2021.01.004","article-title":"Multi-organ proteomic landscape of COVID-19 autopsies.","volume":"184","author":"Nie","year":"2021","journal-title":"Cell"},{"key":"R15-20261117","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.3892\/ijo.2016.3755","article-title":"Silencing of PROS1 induces apoptosis and inhibits migration and invasion of glioblastoma multiforme cells.","volume":"49","author":"Che Mat","year":"2016","journal-title":"Int J Oncol"},{"key":"R16-20261117","doi-asserted-by":"crossref","first-page":"13986","DOI":"10.18632\/oncotarget.14753","article-title":"Protein S drives oral squamous cell carcinoma tumorigenicity through regulation of AXL.","volume":"8","author":"Abboud-Jarrous","year":"2017","journal-title":"Oncotarget"},{"key":"R17-20261117","doi-asserted-by":"crossref","first-page":"e71","DOI":"10.1016\/j.thromres.2009.09.011","article-title":"Expression of protein C (PC), protein S (PS) and thrombomodulin (TM) in human colorectal cancer.","volume":"125","author":"Sierko","year":"2010","journal-title":"Thromb Res"},{"key":"R18-20261117","doi-asserted-by":"crossref","first-page":"124","DOI":"10.3389\/fnmol.2017.00124","article-title":"Protein S negatively regulates neural stem cell self-renewal through Bmi-1 signaling.","volume":"10","author":"Zelentsova-Levytskyi","year":"2017","journal-title":"Front Mol Neurosci"},{"key":"R19-20261117","doi-asserted-by":"crossref","first-page":"e11813","DOI":"10.7717\/peerj.11813","article-title":"Aberrant expression of PROS1 correlates with human papillary thyroid cancer progression.","volume":"9","author":"Wang","year":"2021","journal-title":"PeerJ"},{"key":"R20-20261117","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S1357-2725(01)00155-8","article-title":"Clusterin.","volume":"34","author":"Jones","year":"2002","journal-title":"Int J Biochem Cell Biol"},{"key":"R21-20261117","first-page":"9","article-title":"Chapter 2: clusterin (CLU): from one gene and two transcripts to many proteins.","volume":"104","author":"Rizzi","year":"2009","journal-title":"Adv Cancer Res"},{"key":"R22-20261117","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1007\/s10238-022-00885-2","article-title":"The role and function of CLU in cancer biology and therapy.","volume":"23","author":"Zhang","year":"2023","journal-title":"Clin Exp Med"},{"key":"R23-20261117","doi-asserted-by":"crossref","first-page":"14212","DOI":"10.1074\/jbc.M412569200","article-title":"Delayed activation of insulin-like growth factor-1 receptor\/Src\/MAPK\/Egr-1 signaling regulates clusterin expression, a pro-survival factor.","volume":"280","author":"Criswell","year":"2005","journal-title":"J Biol Chem"},{"key":"R24-20261117","first-page":"449","article-title":"Lipid rafts mediate epigallocatechin-3-gallate- and green tea extract-dependent viability of human colon adenocarcinoma COLO 205 cells; clusterin affects lipid rafts-associated signaling pathways.","volume":"62","author":"Pajak","year":"2011","journal-title":"J Physiol Pharmacol"},{"key":"R25-20261117","doi-asserted-by":"crossref","first-page":"11520","DOI":"10.7150\/thno.44829","article-title":"Inactivation of tumor suppressor gene Clusterin leads to hyperactivation of TAK1-NF-kappaB signaling axis in lung cancer cells and denotes a therapeutic opportunity.","volume":"10","author":"Chen","year":"2020","journal-title":"Theranostics"},{"key":"R26-20261117","doi-asserted-by":"crossref","first-page":"6174","DOI":"10.1158\/0008-5472.CAN-04-0920","article-title":"Intracellular clusterin induces G2-M phase arrest and cell death in PC-3 prostate cancer cells.","volume":"64","author":"Scaltriti","year":"2004","journal-title":"Cancer Res"},{"key":"R27-20261117","doi-asserted-by":"crossref","first-page":"5907","DOI":"10.1073\/pnas.97.11.5907","article-title":"Nuclear clusterin\/XIP8, an x-ray-induced Ku70-binding protein that signals cell death.","volume":"97","author":"Yang","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"key":"R28-20261117","doi-asserted-by":"crossref","first-page":"11590","DOI":"10.1074\/jbc.M209233200","article-title":"Synthesis and functional analyses of nuclear clusterin, a cell death protein.","volume":"278","author":"Leskov","year":"2003","journal-title":"J Biol Chem"},{"key":"R29-20261117","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1002\/jcp.22836","article-title":"Human nuclear clusterin mediates apoptosis by interacting with Bcl-XL through C-terminal coiled coil domain.","volume":"227","author":"Kim","year":"2012","journal-title":"J Cell Physiol"},{"key":"R30-20261117","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1200\/JCO.2014.55.5094","article-title":"BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence.","volume":"32","author":"Xing","year":"2014","journal-title":"J Clin Oncol"},{"key":"R31-20261117","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/S0959-440X(01)00266-4","article-title":"The leucine-rich repeat as a protein recognition motif.","volume":"11","author":"Kobe","year":"2001","journal-title":"Curr Opin Struct Biol"},{"key":"R32-20261117","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.3892\/or.2017.5377","article-title":"Downregulation of leucine-rich-\u03b1-2-glycoprotein 1 expression is associated with the tumorigenesis of head and neck squamous cell carcinoma.","volume":"37","author":"Wang","year":"2017","journal-title":"Oncol Rep"},{"key":"R33-20261117","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.7150\/jca.36189","article-title":"LRG1 suppresses migration and invasion of esophageal squamous cell carcinoma by modulating epithelial to mesenchymal transition.","volume":"11","author":"Zhang","year":"2020","journal-title":"J Cancer"},{"key":"R34-20261117","doi-asserted-by":"crossref","first-page":"11009","DOI":"10.18632\/oncotarget.3557","article-title":"Leucine-rich alpha-2-glycoprotein promotes TGFbeta1-mediated growth suppression in the Lewis lung carcinoma cell lines.","volume":"6","author":"Takemoto","year":"2015","journal-title":"Oncotarget"},{"key":"R35-20261117","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1007\/s12032-015-0598-7","article-title":"LRG1 suppresses the migration and invasion of hepatocellular carcinoma cells.","volume":"32","author":"Zhang","year":"2015","journal-title":"Med Oncol"},{"key":"R36-20261117","doi-asserted-by":"crossref","first-page":"7125","DOI":"10.1007\/s13277-014-1953-6","article-title":"LRG1 is an independent prognostic factor for endometrial carcinoma.","volume":"35","author":"Wen","year":"2014","journal-title":"Tumour Biol"},{"key":"R37-20261117","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s12929-022-00790-6","article-title":"LRG1: an emerging player in disease pathogenesis.","volume":"29","author":"Camilli","year":"2022","journal-title":"J Biomed Sci"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000043715","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T07:01:52Z","timestamp":1794898912000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000043715"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,8]]},"references-count":36,"journal-issue":{"issue":"32","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000043715","relation":{},"ISSN":["1536-5964","0025-7974"],"issn-type":[{"value":"1536-5964","type":"electronic"},{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8,8]]},"assertion":[{"value":"2024-07-16","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-16","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}